Live Breaking News & Updates on Romel Rosales

Stay updated with breaking news from Romel rosales. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

University of Texas at Austin: Hepatitis C Drugs Boost Remdesivir's Antiviral Activity Against COVID-19 – India Education | Latest Education News India | Global Educational News


Share
Remdesivir is currently the only antiviral drug approved in the U.S. for treating COVID-19 patients. In a paper published this week in Cell Reports, researchers from The University of Texas at Austin, Rensselaer Polytechnic Institute (RPI) and the Icahn School of Medicine at Mount Sinai showed that four drugs used to treat hepatitis C render remdesivir 10 times better at inhibiting the coronavirus in cell cultures.
These results indicate that a mixture containing remdesivir and a repurposed hepatitis C virus (HCV) drug could potentially function as a combination antiviral therapy for SARS-CoV-2. Such an antiviral could provide an immediate treatment for unvaccinated people who become infected and for vaccinated people whose immunity has waned. ....

United States , Balasubramanian Harish , Kris White , Thomas Kehrer , Thomasb Acton , Gaetano Montelione , Adolfo Garc , Helena Moreno , Theresaa Ramelot , Catherine Royer , Khushboo Bafna , Robertm Krug , Romel Rosales , University Of Texas At Austin , Icahn School Of Medicine At Mount Sinai , Rensselaer Polytechnic Institute , Cell Reports , Icahn School , Mount Sinai , Lisa Miorin , ஒன்றுபட்டது மாநிலங்களில் , கிரிஸ் வெள்ளை , எலெனா மேலும் , கேத்தரின் ரோயர் , பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் இல் ஆஸ்டின் , இக்ஹ்ன் பள்ளி ஆஃப் மருந்து இல் ஏற்ற சினை ,

Hepatitis C Drugs Boost Remdesivir's Antiviral Activity Against COVID-19


Hepatitis C Drugs Boost Remdesivir’s Antiviral Activity Against COVID-19
Drugs used to treat hepatitis C render remdesivir 10 times better at inhibiting the coronavirus in cell cultures, according to new study. Illustration credit: Jenna Luecke/University of Texas at Austin.
AUSTIN, Texas Remdesivir is currently the only antiviral drug approved in the U.S. for treating COVID-19 patients. In a paper published this week in
Cell Reports, researchers from The University of Texas at Austin, Rensselaer Polytechnic Institute (RPI) and the Icahn School of Medicine at Mount Sinai showed that four drugs used to treat hepatitis C render remdesivir 10 times better at inhibiting the coronavirus in cell cultures. ....

United States , Balasubramanian Harish , Kris White , Thomas Kehrer , Thomasb Acton , Gaetano Montelione , Adolfo Garc , Helena Moreno , Theresaa Ramelot , Catherine Royer , Khushboo Bafna , Robertm Krug , Romel Rosales , University Of Texas At Austin , Icahn School Of Medicine At Mount Sinai , Defense Advanced Research Projects Agency , Department Of Defense , National Institute Of Allergy , National Institutes Of Health , Rensselaer Polytechnic Institute , Cell Reports , Icahn School , Mount Sinai , Lisa Miorin , National Institutes , Computational Innovations ,